Treatment Options for Esophageal Submucosal Cancer, from the Viewpoint of Curative CRT Yoshinori Ito 1 , Rei Kobayashi 1 , Kozo Murakami 1 , Masako Kato 1 , Atsushi Imai 1 , Madoka Morota 1 , Hidenori Shinjo 1 , Akifumi Niiya 1 , Yukiko Ozawa 1 , Kosuke Toyofuku 1 , Emi Nishimura 1 , Atsuhito Sekimoto 1 , Kazunori Miyaura 1 , Yoshikazu Kagami 1 1Department of Radiation Oncology, Showa University School of Medicine, Tokyo Keyword: 食道SM癌 , 化学放射線療法 , CRT , 放射線療法 , 3次元原体照射 , 遅発性有害事象 pp.1273-1282
Published Date 2020/9/25
DOI https://doi.org/10.11477/mf.1403202140
  • Abstract
  • Look Inside
  • Reference

 Definitive chemoradiotherapy for managing cStage I(cT1b)esophageal cancer is recommended in the esophageal cancer practice guidelines as a treatment option for preserving the esophagus in the absence of surgical resection, which is the standard treatment. The recently reported results of JCOG0502 demonstrated that the 5-year survival rate of those receiving definitive chemoradiotherapy was no different from that of patients undergoing esophagectomy. The 5-year esophageal preservation survival rate was 80.4%, a major advantage of definitive chemoradiotherapy. However, the challenge is to prevent the regional recurrence without increasing the number of late adverse events. Elective nodal irradiation(JCOG1904), intensity-modulated radiotherapy, particle therapies such as proton beam therapy and carbon-ion beam therapy, and the combined use of novel anticancer agents are currently being explored.

Copyright © 2020, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院